ClinicalTrials.gg
TerminatedNCT00519532Updated Oct 27, 2014Results posted

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Terminated at 21 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to clinical trial supplies shortage

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
84
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
25th of 42
84 · median 123
Started
2007
with 5 others
Phase 3
20 of 44
none open now
Registered
11th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 25th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 11th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Neupro®
  • Rotigotine
  • Parkinson's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of trial SP889

Exclusion criteria

Exclusion Criteria:

  • Ongoing serious adverse event assessed as related to trial medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine Transdermal Patch

    Drug: Rotigotine

Interventions

  • Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h

    Also known as: Neupro®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)

    The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the elements in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. Baseline is defined as first titration visit (T1) of SP915.

    Time frame: Baseline (baseline SP915) and week 13 (End of maintenance)

  2. Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)

    The Parkinson Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores range between 0= never and 4= very often. Baseline is defined as Visit 2 of previous double- blind trial SP889.

    Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)

Secondary outcomes

  1. Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)

    Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep. Baseline is defined as Visit 2 of previous double- blind trial SP889.

    Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)

  2. Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)

    The change in number of nocturias was used to evaluate improvements in sleep disorders. Baseline is defined as Visit 2 of previous double- blind trial SP889.

    Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)

07

Results

Posted Apr 2, 2010
Limitations and caveats
Because the manufacturing process for rotigotine patches was changed, enrollment into SP915 was stopped in April 2008 to ensure sufficient trial medication for all subjects enrolled at that time to complete the trial according to the protocol.

Participant flow

A total of 84 subjects belong to the Enrolled Set (ES) and all of them received at least 1 dose of trial medication, so they all belong to the Safety Set (SS). 83 subjects belong to the Full Analysis Set (FAS).

Participant flow — Overall Study
MilestoneRotigotine
Started84
Completed66
Not completed18
Withdrew: Adverse event11
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up2

Outcome measures

PrimaryChange From Baseline in UPDRS III Score at Week 13 (End of Maintenance)

The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the elements in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. Baseline is defined as first titration visit (T1) of SP915.

Time frame:
Baseline (baseline SP915) and week 13 (End of maintenance)
Reported as:
Mean · units on a scale
Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)
units on a scaleRotigotine
Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)-5.8 ± 9.4
PrimaryChange From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)

The Parkinson Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores range between 0= never and 4= very often. Baseline is defined as Visit 2 of previous double- blind trial SP889.

Time frame:
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Reported as:
Mean · units on a scale
Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)
units on a scaleRotigotine
Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)-5.8 ± 7.8
SecondaryChange From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)

Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep. Baseline is defined as Visit 2 of previous double- blind trial SP889.

Time frame:
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Reported as:
Mean · units on a scale
Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)
units on a scaleRotigotine
Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)-1.5 ± 2.1
SecondaryChange From Baseline in Number of Nocturias at Week 13 (End of Maintenance)

The change in number of nocturias was used to evaluate improvements in sleep disorders. Baseline is defined as Visit 2 of previous double- blind trial SP889.

Time frame:
Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Reported as:
Mean · Nocturias
Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)
NocturiasRotigotine
Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)-0.4 ± 1.2

Adverse events

Collected over Adverse Events (AEs) were collected over the whole trial period from Visit 1 to the Safety Follow- Up Visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—16/84 (19%)55/84 (65.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventRotigotine
Femoral neck fractureInjury, poisoning and procedural complications3/84
Atrial fibrillationCardiac disorders1/84
Atrioventricular block third degreeCardiac disorders1/84
VomitingGastrointestinal disorders1/84
Reflux oesophagitisGastrointestinal disorders1/84
Inguinal herniaGastrointestinal disorders1/84
Application site vesiclesGeneral disorders1/84
Chest painGeneral disorders1/84
DeathGeneral disorders1/84
OsteomyelitisInfections and infestations1/84
Most frequent other events
Showing 10 of 20
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders11/84
HallucinationPsychiatric disorders11/84
NauseaGastrointestinal disorders10/84
Application site erythemaGeneral disorders10/84
FallInjury, poisoning and procedural complications10/84
DyskinesiaNervous system disorders9/84
DizzinessNervous system disorders9/84
Application site pruritusGeneral disorders8/84
Oedema peripheralGeneral disorders8/84
Pain in extremityMusculoskeletal and connective tissue disorders8/84

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years34
>=65 years49
Age, Continuous
Age, Continuous(years)Rotigotine
Mean66.2 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female26
Male57
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rotigotine
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White71
More than one race0
Unknown or Not Reported9
L- Dopa
L- Dopa(participants)Rotigotine
Early10
Advanced73
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/ m^2)Rotigotine
Mean26.928 ± 4.219
Height
Height(cm)Rotigotine
Mean170.1 ± 10.58
Weight
Weight(kg)Rotigotine
Mean78.3 ± 16.6
08

Study locations

21 sites
  • St. Petersburg, Florida 33701, United States
  • Salisbury, North Carolina 28144, United States
  • Concord, Australia
  • Oulu, 90220, Finland
  • Berlin, 10713, Germany
  • Dresden, 01307, Germany
  • Kassel, 34128, Germany
  • Marburg, 35039, Germany
  • Naumburg, 06618, Germany
  • Ulm, 89081, Germany
  • Budapest, 1145, Hungary
  • Nyiregyhaza, 4400, Hungary
  • Chieti, Italy
  • Milano, 20127, Italy
  • Christchurch, New Zealand
  • Olyszytn, Poland
  • Cape Town, South Africa
  • Barcelona, Spain
  • Madrid, Spain
  • Lancashire, United Kingdom
  • Liverpool, L9 7JL, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2010, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2007
First posted
Aug 22, 2007
Start
Jul 2007
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Apr 2, 2010
Last update
Oct 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00519532
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Aug 22, 2007
Start date
Jul 2007
Primary completion
May 2009
Completion
May 2009
Results posted
Apr 2, 2010
Last update
Oct 27, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion